First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers

Authors

Tiantian Sun (ORCID: https://orcid.org/0000-0002-9216-0989)
Li Guo (ORCID: https://orcid.org/0000-0002-7445-5257)
Lei Gao (ORCID: https://orcid.org/0000-0003-3948-9213)
Yue Hu (ORCID: https://orcid.org/0000-0002-5776-3389)
Wenbo Zheng
Li Liu (ORCID: https://orcid.org/0000-0003-2566-7357)
Hong Zhang (ORCID: https://orcid.org/0000-0002-6191-0046)
Yusi Liu
Ran Peng
Yanhua Ding (ORCID: https://orcid.org/0000-0001-5342-370X)
Dandan Wu

Institutions

Jilin University (CN)
Sino Biopharmaceutical (China) (CN)
First Hospital of Jilin University (CN)

Publication Details

Journal: Expert Opinion on Investigational Drugs
Published: 2025-01-16
DOI: https://doi.org/10.1080/13543784.2025.2453162
Citations: 6
Primary Topic: Asthma and respiratory diseases
Type: article
Field-Weighted Citation Impact: 6.99

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers

Tiantian Sun, Li Guo, Lei Gao, Yue Hu et al.

Jan 16, 2025

6 citations

Expert Opinion on Investigational Drugs

Asthma and respiratory diseases

6.99

article

First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers

Tiantian Sun, Li Guo, Lei Gao, Yue Hu, Wenbo Zheng, Li Liu, Hong Zhang, Yusi Liu, Ran Peng, Yanhua Ding, Dandan Wu

January 16, 2025article en

6 citations

Abstract

No abstract available for this paper.

Expert Opinion on Investigational DrugsVol. 34(1-2)

Jilin University (CN), Sino Biopharmaceutical (China) (CN), First Hospital of Jilin University (CN)

Good health and well-being

Openalex Percentile: Top 3%

Asthma and respiratory diseases

6.99

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

First-in-human study on tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of XKH001, a recombinant humanized monoclonal antibody against IL-25 in healthy Chinese volunteers — Tiantian Sun, Li Guo, et al. · Expert Opinion on Investigational Drugs (2025) | TGRS Research Map | TGRS